semaglutide 5 mg vials Options
The trial attained both of those its primary endpoints, with semaglutide 2.4 mg demonstrating statistically significant and excellent improvements in liver fibrosis with no worsening of steatohepatitis, as well as resolution of steatohepatitis without having worsening of liver fibrosis in people with MASH compared to placebo.1Mumsnet has not checke